Bukh A, Møller-Larsen A, Aguado M T, Møller-Larsen F, Møller N P
Institute of Medical Microbiology, University of Aarhus, Denmark.
Cancer Immunol Immunother. 1988;26(3):280-4. doi: 10.1007/BF00199942.
A total of 50 melanoma patients free of distant metastatic disease and 54 healthy controls were analyzed for circulating immune complexes (cIC) and complement split product (C3d), using solid-phase Clq-anti-IgG radioimmunoassay (RIA), Clq-protein A RIA, and anti-C3d anti-IgG RIA for cIC detection. No significant differences in cIC and C3d levels could be demonstrated between the controls and the 31 patients with primary malignant melanoma analyzed before surgery. To evaluate the prognostic value of serial measurements, samples from the 50 patients were taken at regular intervals for 4 to 27 months (median, 20 months). Surgery was the only treatment given. Significant changes in the cIC and C3d levels were defined by reference to the changes that occurred in 23 of the 54 healthy controls observed for a period of 6 to 55 months (median, 23 months). During the period of serial sampling, recurrent disease developed in 8 of the patients. In only 3 of these 8 patients (versus 10 of 42 patients without recurrence) did significant changes occur, and the changes occurred either at the same time or after the clinical diagnosis of recurrence. During the entire clinical observation period of 6 years, a total of 11 patients developed recurrences. Significant changes were only observed in 4 of these 11 patients versus 8 of 37 patients without recurrence. In conclusion, changes in cIC and/or C3d levels were not found to be indicative of early or long-term recurrence of malignant melanoma.
采用固相Clq-抗IgG放射免疫测定法（RIA）、Clq-蛋白A RIA和抗C3d抗IgG RIA检测循环免疫复合物（cIC）和补体裂解产物（C3d），对50例无远处转移疾病的黑色素瘤患者和54例健康对照进行了分析。在对照组和术前分析的31例原发性恶性黑色素瘤患者之间，未发现cIC和C3d水平有显著差异。为了评估系列测量的预后价值，对50例患者的样本进行了定期采集，时间为4至27个月（中位数为20个月）。手术是唯一给予的治疗。cIC和C3d水平的显著变化是参照54例健康对照中23例在6至55个月（中位数为23个月）观察期内发生的变化来定义的。在系列采样期间，8例患者出现了疾病复发。在这8例患者中，只有3例（与42例未复发患者中的10例相比）出现了显著变化，且这些变化要么与复发的临床诊断同时出现，要么在复发临床诊断之后出现。在整个6年的临床观察期内，共有11例患者出现复发。在这11例患者中，只有4例出现了显著变化，而在37例未复发患者中有8例出现了显著变化。总之，未发现cIC和/或C3d水平的变化可指示恶性黑色素瘤的早期或长期复发。
